Pembrolizumab Shows Exceptional Efficacy in Advanced Desmoplastic Melanoma

20 August 2025
A new study has demonstrated that pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, induces remarkable tumour regression in advanced unresectable desmoplastic melanoma… Read More…